Martin Röcken - Publications#
Selection of important original publications in high impact journals that result exclusively from publicly funded basic and translational research:
IMMUNITY, INFECTION AND AUTOIMMUNE DISEASES#
Guenova E, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M, Kyu-Won Kim KW, Park JH, Seo JH, Ignatov D, Cozzio A, Mitchell P. Levesque MP, Volz T, Köberle M, Kaesler S, Thomas P, Reinhard Mailhammer R, Ghoreschi K, Schäkel K, Amarov B, Eichner M, Schaller M, Clark RA, Röcken M, Biedermann T (2015) IL-4 ab-rogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci USA 112:2163-2168
Skabytska Y, Wölbing F, Günther C, Köberle M, Kaesler S, Chen KM, Guenova E, Demircioglu D, Kempf W, Volz T, Röcken M, Götz F, Biedermann T (2014) Cutaneous innate immune sensing of TLR2/6 ligands suppresses T cell immunity by inducing myeloid derived suppressor cells. Immunity 41: 762-775
Hötzenecker W, Echtenacher B, Guenvoa E, Hötzenecker K, Wölbing F, Brück J, Tes-ke A, Valtcheva N, Fuchs K, Kneilling M, Park JH, Kim KH, Kim KW, Hoffmann P, Krenn C, Hai T, Ghoreschi K, Biedermann T, Röcken M (2012) ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosup-pression. Nat Med 18:128-135
Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O, Hussain RZ, Gocke AR, Respa A, Glocova I, Valtcheva N, Alexander E, Feil S, Feil R, Schulze-Osthoff K, Rupec RA, Lovett-Racke AE, Dringen R, Racke MK, Röcken M (2011) Fumarates im-prove psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208:2291-2303
Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, Mrowietz U, Christophers E, Schlondorff D, Plewig G, Sander CA, Röcken M (2003) Interleukin-4 therapy of psoriasis induces Th2 re-sponses and improves human autoimmune disease. Nat Med 9:40-46
Biedermann T, Zimmermann S, Himmelrich H, Gumy A, Egeter O, Sakrauski AK, Seegmüller I, Voigt H, Launois P, Levine AD, Wagner H, Heeg K, Louis JA, Röcken M (2001) Interleukin 4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2:1054-1060
Biedermann T, Kneilling M, Mailhammer R, Maier K, Sander CA, Kollias G, Kunkel SL, Hültner L, Röcken M (2000) Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 192:1441-1452
TUMOR IMMUNOLOGY AND ONCOLOGY#
Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, Berdel J, Niessner H, Meier F, van den Broek M, Häring HU, Handgretinger R, Quintanilla-Martinez L, Fend F, Pesic M, Bauer J, Zender L, Schaller M, Schulze-Osthoff K, Röcken M (2013) T-helper-1-cell cytokines drive cancer into senescence. Nature 494:361-365 (among 10% best cited from Nature)
Brantsch K, Meisner C, Schönfisch B, Trilling B, Wehner-Caroli J, Röcken M, Breun-inger H (2008) Prospective analysis of the risk factors determining prognosis of cuta-neous squamous cell carcinoma. Lancet Oncol 9:713-720
Müller-Hermelink N, Braumüller H, Pichler B, Kneilling M, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, Förster I, Huss R, Weber WA, Röcken M (2008) TNFR1- and IFN-γ-signaling deter-mine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 6:507-518
Judenhofer MS, Wehrl HF, Newprot DF, Catana C, Siegel SB, Becker M, Thielscher A, Kneilling M, Lichy M, Eichner M, Klingel K, Reischl G, Widmaier S, Röcken M, Nutt RE, Machulla HJ, Uludag K, Cherry SR, Claussen CD, Pichler BJ (2008) Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 14:459-465
Mocikat R, Braumuller H, Gumy A, Egeter O, Ziegler H, Reusch U, Bubeck A, Louis J, Mailhammer R, Riethmuller G, Koszinowski U, Rocken M (2003) Natural killer cells activated by MHC class Ilow targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19:561-569